MSD
Contact UsWorldwide
   
Home Products Research About MSD
Invanz
Online Material
E-mail updates
לתמיכה טכנית




Federation of Infection Societies Conference 2007

Programme - provisional
Satellite Symposium supported by MSD UK Ltd
28th – 30th November 2007, Cardiff City Hall

Making the intelligent choice in antibiotic treatment - when do I need to cover Pseudomonas?
Chair: Professor Fernando Baquero (Ramón y Cajal Hospital, Madrid, Spain) 
View Presentation

The war on resistance: antibiotic stewardship and the role of Ertapenem
Dr Yehuda Carmeli (Beth Israel Deaconess Center, Boston, USA)
View Presentation

Note: The information contained in these presentations represents the independent evaluations and opinions of the author(s) and does not necessarily reflect the opinions and recommendations of MERCK & CO., INC. For detailed information on any drugs discussed herein, please consult the full prescribing information issued by the manufacturer.
 
Federation of Infection Societies Conference 2007

Programme - provisional
Satellite Symposium supported by MSD UK Ltd
28th – 30th November 2007, Cardiff City Hall

Making the intelligent choice in antibiotic treatment - when do I need to cover Pseudomonas?
Chair: Professor Fernando Baquero (Ramón y Cajal Hospital, Madrid, Spain)  
View Presentation

The war on resistance: antibiotic stewardship and the role of Ertapenem
Dr Yehuda Carmeli (Beth Israel Deaconess Center, Boston, USA)
View Presentation

Note: The information contained in these presentations represents the independent evaluations and opinions of the author(s) and does not necessarily reflect the opinions and recommendations of MERCK & CO., INC. For detailed information on any drugs discussed herein, please consult the full prescribing information issued by the manufacturer.
THE ROLE OF CARBAPENEMS IN THE ERA OF ANTIMICROBIAL RESISTANCE

Introduction
Yehuda Carmeli

The Role of Carbapenems: The Predictive Factors for Multi-Drug–Resistant Gram-Negatives
Yehuda Carmeli

Ertapenem: Effect on Gram-Negative Pathogens 19 Months After Formulary Addition
Debra Goff

Study of Infections in Diabetic Feet Comparing Efficacy, Safety and Tolerability of Ertapenem vs. Piperacillin-Tazobactam (SIDESTEP STUDY)
Adolf Karchmer

Questions and Answers

View presentations
ERTAPENEM: THE FIRST GROUP 1 CARBAPENEM Clinical Update

Sections:

  • Medical need for a new nonpseudomonal carbapenem
  • Carbapenem classification
  • Properties of ertapenem
  • Clinical efficacy of ertapenem
  • Appropriate use fo carbapenems

View Presentation
ISSUES IN RESISTANCE

Clinical Implications of Bacterial Resistance
Dr. Kenneth S. Thomson

Summary
Dr. Thomson discusses mechanisms of resistance and their clinical implications, and introduces the concept of  "critical mass."
View Presentation

Current Issues in Antimicrobial Resistance
Dr. George Karam

Summary
Dr. Karam positions resistance as a safety issue and discusses the differences between induction and selection of resistance of various antibiotic classes.
View Presentation

Antimicrobial Resistance
Dr. Ian Friedland (MRL)

Summary
Dr. Friedland presents the mechanism of resistance between ertapenem and imipenem.
View Presentation

The information is provided as service to the medical profession and represents the opinions of the authors, not necessarily those of Merck & Co., Inc. or its affiliates. Due to individual countries' regulatory requirements, indications and uses of products may vary. Before prescribing any products, please consult the local prescribing information available from the manufacturer.
PrintPrintable Version

MSD- Merck Sharp & Dohme, Israel